Aldeyra Therapeutics, Inc. (ALDX)
NASDAQ: ALDX · Real-Time Price · USD
1.570
-0.010 (-0.63%)
At close: Apr 28, 2026, 4:00 PM EDT
1.579
+0.009 (0.59%)
After-hours: Apr 28, 2026, 4:18 PM EDT
Aldeyra Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Aldeyra Therapeutics stock have an average target of 5.50, with a low estimate of 2.00 and a high estimate of 9.00. The average target predicts an increase of 250.32% from the current stock price of 1.57.
Analyst Consensus: Buy
* Price targets were last updated on Mar 18, 2026.
Analyst Ratings
The average analyst rating for Aldeyra Therapeutics stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $10 → $2 | Strong Buy → Hold | Downgrades | $10 → $2 | +27.39% | Mar 18, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +473.25% | Nov 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +536.94% | May 19, 2025 |
| BTIG | BTIG | Strong Buy Maintains $11 → $9 | Strong Buy | Maintains | $11 → $9 | +473.25% | Apr 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +536.94% | Apr 4, 2025 |
Financial Forecast
Revenue This Year
27.66M
Revenue Next Year
16.78M
from 27.66M
Decreased by -39.34%
EPS This Year
-0.47
from -0.56
EPS Next Year
-0.32
from -0.47
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 86.0M | 38.2M | |||||
| Avg | 27.7M | 16.8M | |||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | 38.0% | |||||
| Avg | - | -39.3% | |||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | -0.39 | -0.25 | |||||
| Avg | -0.47 | -0.32 | |||||
| Low | -0.63 | -0.41 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | - | - | |||||
| Avg | - | - | |||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.